Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial (2018)
Journal Article
Hutchinson, A., Rees, S., Young, A., Maraveyas, A., Date, K., & Johnson, M. J. (2019). Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliative medicine, 33(5), 510-517. https://doi.org/10.1177/0269216318815377

Background: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label,... Read More about Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer (2017)
Journal Article
Date, K., Ettelaie, C., & Maraveyas, A. (2017). Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. Journal of thrombosis and haemostasis : JTH, 15(12), 2289-2299. https://doi.org/10.1111/jth.13871

© 2017 International Society on Thrombosis and Haemostasis Summary: Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact mechanisms for the induction of VTE remain to be fully elucidated, but it is widely acknowledge... Read More about Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.